TP53 and acute myeloid leukemia: Different clinical studies have uniformly reported a correlation between TP53 mutations and resistance to lenalidomide in del(5q) MDS [93,94], in terms of a reduced response rate, poorer OS, the appearance and/or increase of TP53-mutant clones, and a higher risk of AML transformation compared to WT patients [7].